Reviva Pharmaceuticals (RVPH) Holdings announced that it intends to offer shares of its common stock and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals price target lowered to $7 from $14 at Benchmark
- Reviva Pharmaceuticals Advances Schizophrenia Treatment
- Reviva Pharmaceuticals price target lowered to $2 from $5 at Maxim
- Reviva Pharmaceuticals price target lowered to $3 from $7 at Roth Capital
- Reviva Pharmaceuticals reports Q2 EPS (12c) vs. (26c) last year